2017 Fiscal Year Final Research Report
Novel immunotherapy with HDAC inhibitor and OK-432 targeting PD-1
| Project/Area Number |
15K11293
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Surgical dentistry
|
|---|
| Research Institution | The University of Tokushima |
|---|
Principal Investigator |
OHE Go 徳島大学, 病院, 助教 (60432762)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
玉谷 哲也 徳島大学, 病院, 講師 (30274236)
高丸 菜都美 徳島大学, 病院, 助教 (40513031)
永井 宏和 東北大学, 歯学研究科, 准教授 (50282190)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Keywords | PD-L1 / PD-1 / 免疫チェックポイント / OK-432 / 口腔癌 |
|---|
| Outline of Final Research Achievements |
Tumor bearing mice were treated with anti PD-L1 Ab and/or OK-432, and the mechanism of antitumoe effect was analyzed.PD-L1 was not expressed on untreated SCCVII cells, but after adding IFN-γ, PD-L1 was expressed. anti PD-L1 Ab couldn't demonstrated directly effective on SCCVII proliferation (MTT assay). Combination therapy anti PD-L1 Ab and OK-432 inhibited tumor growth of SCCVII bearing mice.
It was suggested that combination therapy anti PD-L1 Ab and OK-432 could be an effective therapy against oral cancer.
|
| Free Research Field |
腫瘍免疫学
|
